The influence of monoamine oxidase inhibitors and some other antidepressants on the anti-parkinsonian activity of sub-effective doses of diphenylhydramine in rats and mice.
D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002389:Catatonia / Q000139:chemically induced / Q000188:drug therapy; D004155:Diphenhydramine / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D051379:Mice; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage*; D009661:Nortriptyline / Q000627:therapeutic use; D010276:Parasympatholytics / Q000008:administration & dosage*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000517:prevention & control; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010546:Perphenazine; D010624:Phenelzine / Q000627:therapeutic use; D051381:Rats; D014203:Tremorine
D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D010276:Parasympatholytics; D004155:Diphenhydramine; D009661:Nortriptyline; D010546:Perphenazine; D010624:Phenelzine; D014203:Tremorine